← 홈

전체 프로그램

ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 201개
AntibodystaleHospital Universitario Dr. Jose…Phase 2

Low-dose teclistamab (Low-dose teclistamab)

Multiple Myeloma, Newly Diagnosed · Multiple Myeloma, Newly Diagnosed

#MultipleMyelomaNewlyDiagnosed#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
CGTBiologicstaleMemorial Sloan Kettering Cancer…Phase 1

MCARH109 (MCARH109)

Multiple Myeloma; Refractory Multiple Myeloma · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
CGTBiologicstaleMemorial Sloan Kettering Cancer…Phase 1

MCARH125 (MCARH125)

Multiple Myeloma; Refractory Multiple Myeloma · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
AntibodystalePfizerPhase 1

Maplirpacept (Maplirpacept)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystalePfizerPhase 1

PF-07901801 (Maplirpacept, Maplirpacept (PF-07901801))

Lymphoma; Multiple Myeloma · Lymphoma

#Lymphoma#Antibody#Phase1#항체#면역항체+3
임상시험 1상태 DISCONTINUED
CGTBiologicstaleLeman Biotech Co., Ltd.Phase 1

Metabolically Armed BCMA CAR-T cells. (Metabolically Armed BCMA CAR-T cells.)

Multiple Myeloma (MM); Plasma Cell Leukemia (PCL) · BCMA

#BCMA#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
AntibodystaleJanssenPhase 2

daratumumab (Darzalex, Mitoxantrone hydrochloride liposome/Dexamethasone/daratumumab)

Relapsed/Refractory Multiple Myeloma · FRα

#FR#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 ACTIVE
CGTBiologicstaleUniversity of PennsylvaniaPhase 1

NY-ESO-1 redirected autologous T cells with CRISPR edited endogenous TCR and PD-1 (NY-ESO-1 redirected autologous T cells with CRISPR edited endogenous TCR and PD-1)

Multiple Myeloma; Melanoma · PD-1

#PD-1#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 DISCONTINUED
CGTBiologicstaleHadassah Medical OrganizationPhase 1

Naive HBI0101 CAR-T (Naive HBI0101 CAR-T)

Relapsed/Refractory Multiple Myeloma (MM) · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
CGTBiologicstalePoseida Therapeutics, Inc.Phase 2

P-BCMA-101 CAR-T cells (P-BCMA-101 CAR-T cells)

Multiple Myeloma · BCMA

#BCMA#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 1상태 DISCONTINUED
CGTBiologicstalePoseida Therapeutics, Inc.Phase 1

P-BCMA-ALLO1 CAR-T cells (P-BCMA-ALLO1 CAR-T cells)

Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
CGTBiologicstalePrecision BioSciences, Inc.Phase 1

PBCAR269A (PBCAR269A)

Relapsed/Refractory Multiple Myeloma · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 DISCONTINUED
CGTBiologicstaleDaihong LiuPhase 2

PD-1Ab21-BCMA CAR-T cell immunotherapy (PD-1Ab21-BCMA CAR-T cell immunotherapy)

Multiple Myeloma · PD-1

#PD-1#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
AntibodystaleJanssenPhase 2

daratumumab (Darzalex, Part 1, Dose Escalation, Part 1 (Dose Escalation): Daratumumab)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase2#항체#면역항체+2
효능 ORR 81.3%임상시험 1상태 ACTIVE
AntibodystaleJanssenPhase 2

daratumumab (Darzalex, Part 1: Daratumumab)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase2#항체#면역항체+2
효능 ORR 33.3%임상시험 1상태 ACTIVE
AntibodystaleJanssenPhase 2

daratumumab (Darzalex, Part 2, Dose Expansion, Part 2 (Dose Expansion): Daratumumab)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase2#항체#면역항체+2
효능 ORR 81.3%임상시험 1상태 ACTIVE
AntibodystaleJanssenPhase 2

daratumumab (Darzalex, Part 2: Daratumumab)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase2#항체#면역항체+2
효능 ORR 33.3%임상시험 1상태 ACTIVE
ADCBiologicstaleGlaxoSmithKlinePhase 3

Pomalidomide plus low dose Dexamethasone (Pom/dex, Pom/dex (Pomalidomide plus low dose Dexamethasone))

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+1
효능 ORR 41%임상시험 1상태 RECRUITING
AntibodystaleJanssenPhase 2

daratumumab (Darzalex, QL2109 or Daratumumab)

Relapsed or Refractory Multiple Myeloma · FRα

#FR#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleRegeneron PharmaceuticalsPhase 2

REGN17372+Linvoseltamab (REGN17372+Linvoseltamab)

Relapsed Refractory Multiple Myeloma (RRMM) · FRα

#FR#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING

9 / 11 페이지

← 이전다음 →